Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '2540.0036.75

Profile

Edit
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 30, 2025 (est.)
Last Earnings Release Feb. 11, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
URL https://www.exelixis.com
Investor Relations URL https://ir.exelixis.com
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 30, 2025 (est.)
Last Earnings Release Feb. 11, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows